AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Not yet recruiting 36 enrolled Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NaSingle-groupOpen-labelTreatment

Summary

This exploratory phase II study is designed to enroll patients with operable locally advanced head and neck squamous cell carcinoma, to observe the efficacy and safety of AK112 combined with chemotherapy as neoadjuvant therapy on them.

Timeline

Start: 2024-08-01
Primary completion: 2027-07-15
Completion: 2028-07-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ivonescimab	Monoclonal antibody	20 mg/kg	—

Indications

No indication recorded.